Pacari (Lafoensia glyptocarpa)

Pacari (Lafoensia glyptocarpa) is an Amazonian medicinal plant whose bark and leaves are rich in ellagitannins and punicalagin-related polyphenols that drive its therapeutic effects. These bioactives promote wound healing primarily by stimulating collagen synthesis, neoangiogenesis, and scavenging reactive oxygen species at the cellular level.

Origin & History

Pacari, also known as Lafoensia glyptocarpa, is a semi-deciduous tree native to Brazil and Paraguay. It grows in various forest types and is harvested for its leaves, bark, and stems, which are rich in polyphenols and flavonoids.

Historical & Cultural Context

In Brazilian folk medicine, Pacari has been traditionally used for wound healing, cutaneous mycoses, gastritis, ulcers, and inflammation. Its use is rooted in native practices from the Cerrado regions.

Health Benefits

• Promotes wound healing, enhancing collagen production and neoangiogenesis in preclinical studies.
• Exhibits anti-inflammatory effects, as seen in in vivo/in vitro models.
• Acts as a reactive oxygen species (ROS) scavenger, aiding in cellular protection.
• Modulates remodeling processes in wound healing, improving recovery phases.
• No adverse effects reported in rat studies, indicating potential safety for topical use.

How It Works

Pacari's ellagitannins and phenolic acids inhibit pro-inflammatory mediators, including NF-κB pathway activation and COX-derived prostanoids, reducing cytokine release such as TNF-α and IL-6 in inflamed tissues. Its polyphenolic compounds act as direct ROS scavengers by donating hydrogen atoms to neutralize superoxide and hydroxyl radicals, thereby protecting cellular membranes and DNA from oxidative damage. Additionally, these bioactives upregulate TGF-β1 signaling and VEGF expression, stimulating fibroblast collagen deposition and endothelial cell proliferation required for neoangiogenesis during wound remodeling.

Scientific Research

There are no human clinical trials or meta-analyses available for Pacari. Research is limited to animal models and in vitro studies, such as a rat study showing enhanced wound healing properties.

Clinical Summary

Current evidence for Lafoensia glyptocarpa is limited to preclinical in vitro cell culture studies and in vivo rodent wound-healing models, with no published randomized controlled trials in humans identified to date. In animal excision wound models, topical preparations of Pacari extract have demonstrated accelerated wound closure rates and increased hydroxyproline content, an indirect marker of collagen deposition, compared to untreated controls. Anti-inflammatory effects have been confirmed in carrageenan-induced paw edema models in rodents, showing statistically significant edema reduction. The overall evidence base is preliminary and promising but insufficient to establish clinical dosing recommendations or confirm efficacy in human populations.

Nutritional Profile

Pacari (Lafoensia glyptocarpa) nutritional data is limited in the peer-reviewed literature, as research has focused predominantly on its bioactive phytochemical constituents rather than macronutrient composition. Known and characterized compounds include: Ellagitannins and ellagic acid (primary bioactive polyphenols, estimated 2–8% dry weight in bark/leaf extracts, responsible for antioxidant and wound-healing activity); Gallic acid and its derivatives (quantified at approximately 0.5–3% dry weight in hydroalcoholic extracts); Flavonoids including quercetin and kaempferol glycosides (present at trace to moderate levels, <1% dry weight); Tannins (hydrolyzable type, estimated 5–15% dry weight in bark extracts, contributing to ROS-scavenging capacity); Pentacyclic triterpenes such as ursolic and oleanolic acid (detected in leaf fractions at <1% dry weight). Regarding conventional nutrients: crude fiber content is present but not precisely quantified in available literature; protein and lipid content are considered low based on analogous Lythraceae species. Mineral content has not been systematically characterized. Bioavailability notes: ellagic acid from ellagitannins undergoes gut microbial conversion to urolithins (A and B), which may enhance systemic anti-inflammatory and antioxidant bioavailability; tannin-protein binding may reduce protein digestibility if consumed in food matrices. No standardized nutritional panel (USDA-style) currently exists for this species.

Preparation & Dosage

There are no clinically studied dosage ranges in humans. A 10% leaf extract gel was used in preclinical rat studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric, Ginger, Ashwagandha, Ginseng, Green Tea

Safety & Interactions

No formal human clinical safety trials for Lafoensia glyptocarpa have been published, making a complete adverse effect profile unavailable at this time. Given its high tannin content, oral consumption at elevated doses may cause gastrointestinal irritation, nausea, or constipation, effects consistent with other ellagitannin-rich botanicals. Due to its demonstrated anti-inflammatory and potential anticoagulant-like polyphenol activity, caution is advised when combining Pacari with anticoagulant or antiplatelet drugs such as warfarin or aspirin, as additive bleeding risk cannot be excluded. Pregnant and breastfeeding individuals should avoid use due to an absence of safety data, and individuals with tannin sensitivities or chronic gastrointestinal conditions should consult a healthcare provider before use.